Sanuwave Health (NASDAQ:SNWV) Earns Buy Rating from Analysts at Roth Capital

Roth Capital assumed coverage on shares of Sanuwave Health (NASDAQ:SNWV) in a report issued on Tuesday, Marketbeat reports. The brokerage set a “buy” rating and a $49.00 price target on the stock. Roth Capital’s target price would indicate a potential upside of 36.15% from the stock’s previous close.

Separately, Wall Street Zen lowered Sanuwave Health from a “buy” rating to a “hold” rating in a research note on Saturday, May 24th.

Sanuwave Health Price Performance

Sanuwave Health stock opened at $35.99 on Tuesday. The firm has a market capitalization of $308.43 million, a price-to-earnings ratio of -7.90 and a beta of 1.24. Sanuwave Health has a fifty-two week low of $5.21 and a fifty-two week high of $39.83. The firm has a fifty day moving average price of $32.33.

Sanuwave Health (NASDAQ:SNWV) last posted its quarterly earnings data on Friday, May 9th. The company reported ($0.66) EPS for the quarter. The company had revenue of $9.34 million during the quarter.

Insiders Place Their Bets

In other Sanuwave Health news, insider Iulian Cioanta sold 3,639 shares of the firm’s stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $31.60, for a total value of $114,992.40. Following the sale, the insider directly owned 41 shares of the company’s stock, valued at approximately $1,295.60. This trade represents a 98.89% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Peter Stegagno sold 1,862 shares of Sanuwave Health stock in a transaction dated Thursday, June 5th. The shares were sold at an average price of $27.71, for a total value of $51,596.02. Following the completion of the sale, the chief operating officer owned 2,032 shares of the company’s stock, valued at $56,306.72. This trade represents a 47.82% decrease in their position. The disclosure for this sale can be found here. 14.90% of the stock is owned by company insiders.

Institutional Trading of Sanuwave Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Strategic Investment Solutions Inc. IL purchased a new stake in shares of Sanuwave Health during the 1st quarter worth about $47,000. Solas Capital Management LLC purchased a new stake in shares of Sanuwave Health during the 1st quarter worth about $20,658,000. AWM Investment Company Inc. purchased a new stake in shares of Sanuwave Health during the 1st quarter worth about $18,153,000. Goldman Sachs Group Inc. purchased a new stake in shares of Sanuwave Health during the 1st quarter worth about $337,000. Finally, Evernest Financial Advisors LLC purchased a new stake in shares of Sanuwave Health during the 2nd quarter worth about $823,000. Hedge funds and other institutional investors own 42.53% of the company’s stock.

Sanuwave Health Company Profile

SANUWAVE Health, Inc, a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures.